EUCTR2016-000972-91-SK进行中（未招募）1 期
A randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab to demonstrate efficacy in the treatment of enthesitis at the Achilles tendon up to 1 year in adult patients with active Psoriatic Arthritis (PsA) and axial Spondyloarthritis (axSpA) (ACHILLES) - ACHILLES
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Psoriatic arthritis patients must fulfill the following criteria:
- •Diagnosis of Psoriatic arthritis classified by Classification criteria for Psoriatic Arthritis (CASPAR criteria) with symptoms for at least 6 months and active Psoriatic arthritis as assessed by > 1 tender joints out of 78 and > 1 swollen joints out of 76 at Baseline (dactylitis of a digit counts as one joint each)
- •- Axial Spondyloarthritis patients must fulfill the following criteria:
- •Axial Spondyloarthritis as per the classification of the Assessment of Spondyloarthritis International Society axial Spondyloarthritis (ASAS) criteria with objective signs of inflammation at Screening (magnetic resonance imaging (MRI) with Sacroiliac joint inflammation or definite radiographic sacroilitis according to the modified New York (NY) criteria and/or abnormal high sensitivity C-Reactive Protein (hsCRP)) and active disease assessed by total Bath ankylosing spondylitis disease activity index (BASDAI) = 4 (0–10) at Baseline
- •- Diagnosis of Achilles tendon enthesitis according to swelling and tenderness at the insertional site of the Achilles tendon into the calcaneus
- •- Onset of heel pain = 1 month up to 5 years at Baseline
- •- Heel enthesitis that is magnetic resonance imaging (MRI)-positive according to the investigator`s judgement
- •- Patients who are Tumor necrosis factor (TNF) inhibitor-naive
- •Other protocol defined inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 180
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process
- •- Previous exposure to secukinumab or other biologic drug directly targeting Interleukin (IL)-17 or Interleukin (IL)-17 receptor
- •- Ongoing use of psoriasis treatments / medications (e.g. topical corticosteroids, ultraviolet (UV) therapy) at randomization
- •- Patients who have previously been treated with Tumor necrosis factor (TNF) inhibitors (investigational or approved).
- •- Patients who have ever received biologic immunomodulating agents (investigational or approved)
- •- Pregnant or nursing (lactating) women
- •- History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection
- •Other protocol defined exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
Study of efficacy and safety of secukinumab in Psoriatic Arthritis and axial Spondyloarthritis patients withactive enthesitis including one Achilles tendon site (ACHILLES)Psoriatic arthritisAxial spondyloarthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 21.1Level: PTClassification code 10071400Term: Axial spondyloarthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2016-000972-91-GBovartis Pharma Services AG204
进行中（未招募）
1 期
Study of efficacy and safety of secukinumab in patients with non-radiographic axial spondyloarthritis.on-radiographic axial spondyloarthritisMedDRA version: 20.0Level: LLTClassification code 10076297Term: Non-radiographic axial spondyloarthritisSystem Organ Class: 100000004859EUCTR2015-001106-33-ITOVARTIS PHARMA SERVICES AG555
进行中（未招募）
1 期
Study of efficacy and safety of secukinumab in patients with non-radiographic axial spondyloarthritisEUCTR2015-001106-33-ESovartis Farmacéutica S.A.555
进行中（未招募）
1 期
Study of safety and efficacy of ianalumab in patients with primary Sjogren’s Syndrome (pSS)Primary Sjogren’s syndromeMedDRA version: 21.0Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2016-003292-22-DEovartis Pharma AG180
尚未招募
1 期
A randomized, double-blind, placebo-controlled multicenter clinical study of Xifeng Huashi Granules in the treatment of diarrheal irritable bowel syndromeITMCTR2000004143Jiangsu Provincial Hospital of Integrated Traditional Chinese and Western Medicine